新浪登录
腾讯登录Northwestern大学推出新的个性化肿瘤项目
| 导读 | 近日，西北大学综合癌症中心的Robert H. Lurie宣布与西北大学医学发展治疗研究所（NMDTI）、西北Memorial医院合作推出一个新的精确医疗研究项目，其综合了免疫和基因组，称作Northwestern Onco-SET（测序、评估、治疗）。 |
近日，西北大学综合癌症中心的Robert H. Lurie宣布与西北大学医学发展治疗研究所（NMDTI）、西北Memorial医院合作推出一个新的精确医疗研究项目，其综合了免疫和基因组，称作Northwestern Onco-SET（测序、评估、治疗）。
“Onco-SET将提供基础环境和设施，使我们可以对患者进行个性化的癌症治疗，这在当前来说是十分少见的，同时我们将加快别的研究，这些研究将关注于为患者制定新颖的个性化治疗方案”劳瑞癌症中心副主任、NMDTI主任Francis Giles在声明中这样说。
该项目的特色是新创建的劳瑞癌症中心分子肿瘤董事会，这将使专家们聚在一起，检查每一个癌症患者的基因组，并对每一个患者进行评估，选择最佳的治疗方案。董事会将包括一系列的癌症专家，包括病理学家、内科、外科和放射肿瘤学家，以及癌症遗传学家，生物基因组学家、生物伦理学家和生物信息学家。劳瑞癌症中心的主任Leonidas Platanias说，多学科的项目会运用分子基因组确定的靶向来选择治疗方案，这包括了新颖的早期临床实验。
该中心说，该项目将首先关注对传统疗法没有反应的癌症患者。
在2014年十一月，劳瑞癌症中心和NMDTI宣布，他们将创造一个转化医学项目来开发癌症治疗方式，该项目获得了医学基金会的支持。去年十二月，该组织宣布，他们将与eoGenomics展开合作。（转化医学网360zhyx.com）
以上为转化医学网原创翻译整理。如需转载，请联系 info@360zhyx.com。
原文：The Robert H. Lurie Comprehensive Cancer Center of Northwestern University today announced a collaboration with the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) andNorthwestern Memorial Hospitalto launch a precision medicine research program combining oncology and genomics called Northwestern Onco-SET (Sequence, Evaluate, Treat)."Onco-SET will provide the environment and infrastructure in which we can deliver personalized cancer treatment for patients who currently have very limited options, while accelerating our other research focused on developing novel individually tailored agents," Francis Giles, deputy director of the Lurie Cancer Center and director of NMDTI, said in a statement.
A feature of the program is the newly created Lurie Cancer Center Molecular Tumor Board, which will bring experts together to review every tumor's genomic profile to evaluate the best treatment options for each patient. The board will consist of a range of cancer specialists, including pathologists, medical, surgical, and radiation oncologists, as well as cancer geneticists, genome biologists, bio-ethicists, and bioinformaticists. Leonidas Platanias, director of the Lurie Cancer Center, said that the multidisciplinary program would use molecularly defined genomic targets to determine treatment options including novel early-phase clinical trials.
The program will initially focus on patients with cancers that are not responsive to traditional therapies, the center said.
In November 2014, the Lurie Cancer Center and the NMDTI announced they would create a translational medicine program to develop cancer therapeutics, with backing from Foundation Medicine. In December, the organizations announced they would also collaborate with NeoGenomics.
还没有人评论，赶快抢个沙发